New developments in iron chelators

Current Opinion in Hematology

Volumn 12, Issue 2, 2005, Pages 129-134

  Cunningham, Melody J ^a,b,c,d   Nathan, David G ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Department of Medicine   (United States)

Author keywords

Chelation; Iron; Thalassemia

Indexed keywords

40SD02; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG;

CHELATION THERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; REVIEW;

HEART DISEASES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; THALASSEMIA;

EID: 14644438604     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000152631.63469.07     Document Type: Review

References (50)

1. Smith RS. Chelating agents in the diagnosis and treatment of iron overload in thalassemia. Ann N Y Acad Sci 1964; 119:776-788.
2. Waxman HS, Brown EB. Clinical usefulness of iron chelating agents. Prog Hematol 1969; 6:338-373.
3. Barry M, Flynn M, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: Effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974; 2:16-20.
4. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297:418-423.
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193. A comprehensive review of nearly 1700 patients treated at seven Italian teaching hospitals. There is a review of survival and complication-free survival based on birth cohort demonstrating progressive improvement in patients with thalassemia.
6. Sonakul D, Pacharee P, Thakerngpol K. Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Orig Artic Ser 1988; 23:157-176.
7. Sonakul D, Thakerngpol K, Pacharee P. Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Artic Ser 1988; 23:177-191.
8. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload; Redox activity and susceptibility to chelation. Blood 2003; 102:2670-2677. This paper reviews the information known regarding NTBI and furthers the evaluation by studying labile plasma iron and directly chelatable iron as measures that may be helpful in vivo in assessing chelation efficacy.
9. Pootrakul P, Breuer W, Sametband M, et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004; 104:1504-1510. This paper evaluated labile plasma iron and directly chelatable iron in patients receiving deferiprone.
10. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106:147-153.
11. Miskin H, Yaniv I, Berant M, et al. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003; 70:398-403. An important, possibly alternative, chelation strategy is presented and evaluated retrospectively in a small population of noncompliant patients and may suggest a viable approach to patients who, despite 'requiring' 24/7 chelation for cardiac complications, are unable to comply and continue to deteriorate.
12. Hershko C, Cappellin MD, Galanello R, et al. Purging iron from the heart. Br J Haematol 2004; 125:545-551. Comprehensive review of myocardial siderosis and evidence for deferiprone and deferoxamine in cardiac siderosis.
13. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95:1229-1236.
14. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850:227-231.
15. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99-109.
16. Ehlers KH, Giardina PJ, Lesser ML, et al. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991; 118:540-545.
17. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004; 104:34-39. This is a comprehensive, albeit on time, registry data collection and review of 342 North American patients with thalassemia.
18. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol 2002; 509:91-125.
19. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol 2002; 15:329-368.
20. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675.
21. St Pierre TG, Clark PR, Chua-anusorn W, et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105:855-861. Report of data on 105 subjects evaluating the correlation between liver iron content by biopsy and R2 MRI. Reviews the methodology and technology.
22. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-2179.
23. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127:348-355. Prospective study of seven patients placed on intravenous deferoxamine for iron-induced cardiac disease. The patients were noted to have statistically improved LVEF, liver iron, and cardiac iron as measured by T2* MRI. Cardiac iron was noted to decrease more slowly than liver iron.
24. St Pierre TG. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:182-184.
25. Fischer R, Engelhardt R. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:182-183.
26. Brittenham GM, Nathan DG, Olivieri N, et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:183-184.
27. Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361:184.
28. Cann CE, Quill L, Koerper M, Mentzer W. Non-invasive estimation of cardiac hemosiderosis by quantitated computed tomography. 23rd Annual Meeting, National Sickle Cell Disease Program, San Francisco. San Francisco, California: National Sickle Cell Disease Program; 1999.
29. Goldberg HI, Cann CE, Moss AA, et al. Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. Invest Radiol 1982; 17:375-380.
30. Lipton MJ, Cann CE, Goldberg HI, et al. Dual energy CT for quantitating myocardial iron levels in haemochromatosis. American Heart Association Abstracts of the 54th Scientific Sessions. Circulation 1981; 64:IV-221.
31. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104:263-269. Review of 81 patients who had intensification of their chelation therapy based on decreasing cardiac ejection fraction. Demonstrates the importance of careful annual monitoring of cardiac function and the improved outcomes with aggressive early intervention.
32. Yang T, Brittenham GM, Dong WQ, et al. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003; 142:332-340.
33. Wali YA, Taqi A, Deghaidi A. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Pediatr Hematol Oncol 2004; 21:453-460. Presents prospective data on very aggressive chelation therapy requiring inpatient admissions frequently for short duration in patients who are noncompliant. This may offer an alternative for patients who are prescribed 24/7 chelation but are unable to comply.
34. Harmatz P, Grady WB, Vichinsky E. A phase Ib study of safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02 (CHF 1540, GS 460) in iron-loaded patients. Blood 2003; 102:121a.
35. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17-24. Review of the deferiprone data, including reviews, studies, and reports in the literature as of 2003. Provides summary details of outcomes including ferritin, liver iron, cardiac iron, and adverse events.
36. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (American Society of Hematology Education Program). American Society of Hematology, Washington, D.C. 2003; pp 40-61. Reviews hemochromatosis, iron chelation therapy, and iron deficiency anemia.
37. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583-1587. Four-year follow-up data on patients who were early reported in a 1-year prospective study of chelation treatment with deferiprone. No useful measurements of efficacy are provided.
38. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122:305-310. Nine patients with thalassemia not requiring chronic transfusion therapy were given lower than the 'standard' dose of deferiprone and demonstrated decreases in liver iron, ferritin, and red blood cell membrane iron.
39. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489-496. This retrospective review of deferiprone versus deferoxamine in patients with thalassemia major reported improved cardiac outcomes in patients treated with deferiprone. Much controversy was generated by this because of the retrospective nature and the fact that the two groups did not seem well matched.
40. D'Angelo E, Mirra N, Rocca A, Carnelli V. Combined therapy With Desferrioxamine and Deferiprone: a New Protocol for Iron Chelation in Thalassemia. J Pediatr Hematol Oncol 2004; 26:451-453.
41. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121:187-189. Randomized, controlled study of patients with transfusion-dependent thalassemia comparing deferoxamine alone to deferoxamine and deferiprone demonstrating that the combination therapy, with both drugs at standard doses, could be given safely.
42. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43:565-572. Preliminary study of ICL670 that demonstrated its safety in single doses up to as high as 80 mg/kg.
43. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361:1597-1602. Iron-balance study of ICL670 that demonstrated equal efficacy of 20 mg/kg of ICL670 and 40 mg/kg of deferoxamine and demonstrated the 24-hour blood levels of ICL670, which may be of benefit as protection against iron-induced free radical damage.
44. Piga A, Galanello R, Cappellini M, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003; 102:121A. Although published thus far only in abstract form, it reports the only published data on the largest group of patients treated with ICL670 for a prolonged period of time.
45. Bergeron RJ, Wiegand J, Brittenham GM. HBED ligand: Preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 2002; 99:3019-3026.
46. Link G, Ponka P, Konijn AM, et al. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 2003; 101:4172-4179.
47. Wong C, Richardson DR. Beta-thalassaemia: Emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 2003; 35:1144-1149.
48. Marquis JK, Aoude-Dagher R, Guillumat PO. Pharmacology and toxicology of GT56-252, a novel orally available iron chelator. 12th International Conference on Oral Chelation in the Treatment of Thalassaemia & Other Disease. ICOC Santorini 2002; p. 112.
49. Donovan JM, Palmer PA, Plone MA, Wonke B. The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator. 38th Annual Meeting of the European Society for Clinical Investigation. Eur J of Clin Invest 2004; 139:39.
50. Cohen A, Galanello R, Pennell DJ, et al. Thalassemia. Hematology (Am Soc Hematol Educ Program) American Society of Hematology, Washington, D.C. 2004; 14-34.